Dis-Chem sees double-digit earnings and dividend growth

Loading player...
GUEST - Rui Morais, CEO of Dis-Chem
South African pharmacy group Dis-Chem reported a 16.3% jump in headline earnings for the six months ended 31 August 2024, it announced on Sens on Friday.
Dis-Chem also posted a 16.1% surge in its dividend per share, which amounts to 26.98 cents, compared to 23.2 cents in the corresponding period in 2023.
The group’s share price traded over 2% lower on Friday morning, at around R36.35 a share.
Dis-Chem attributes the strong earnings growth largely to the containment of group payroll costs, predominantly driven by the successful deployment of its ‘staffing framework 1.0’-strategy. Staffing framework 1.0 focuses on achieving the optimal mix of staff to ensure efficient operations at store level.
In the period under review, Dis-Chem’s like-for-like retail employee costs increased by just 0.7%, but wholesale expenses jumped 13.2% – mainly as a result of the acquisition of the Longmeadow warehouse in Gauteng.
For the half-year, Dis-Chem saw its revenue rise by 9.6% to R19.6 billion, while operating profit surged 17.5%.
Six new retail pharmacy stores were opened, resulting in 274 retail pharmacy stores and 53 retail baby stores as at 31 August 2024, it noted.
28 Oct 2024 2PM English South Africa Business News · Investing

Other recent episodes

SA Homeowner growth steady, report finds

Hayley Ivins-Downes from Lightstone Property shares data about home-buying activity in South Africa, which paints an interesting picture about affordability and which specific parts of the country are seeing the most development.
27 Mar 5AM 11 min

INSIDE YOUR POCKET – South Africa’s consumer credit market steady

Data from TransUnion shows that South African credit usage has shown tentative recovery to a more broad-based recovery, with first-time buyers now accounting for just over half of financed purchases. Ayeshaa Hatea, from TransUnion South Africa, explains these findings and more.
27 Mar 5AM 11 min

Pivot Point - Building Africa’s Vaccine Sovereignty

Today on Pivot Point, we spotlight a leader whose work sits at the intersection of science, industrialization, and national security. Dr. Morena Makhoana, the CEO of Biovac, has spent two decades shaping South Africa’s vaccine manufacturing landscape and unpacks that journey.
27 Mar 5AM 25 min

Africa’s Trade Links Strengthen; Future Geopolitical Risks Loom

Data from Standard Bank signalled significant growth in intra-African trade in the past year, showing positive moment towards the continent achieving a successful AfCFTA. However, that picture could be complicated by recent tensions in the Middle East. For more on this let’s listen in to, Philip Myburgh, Head: Trade for…
25 Mar 4PM 12 min